NYMX.F Stock Overview
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Nymox Pharmaceutical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.30 |
| 52 Week High | US$1.28 |
| 52 Week Low | US$0.12 |
| Beta | 0.32 |
| 1 Month Change | -14.29% |
| 3 Month Change | -35.95% |
| 1 Year Change | -25.69% |
| 3 Year Change | -85.29% |
| 5 Year Change | -83.78% |
| Change since IPO | -95.27% |
Recent News & Updates
Recent updates
Nymox gets FDA feedback on NDA resubmission for lead asset
Sep 13Is Nymox Pharmaceutical (NASDAQ:NYMX) In A Good Position To Deliver On Growth Plans?
Aug 17
NYMOX stock down 7.2% after receiving non-compliance letter from Nasdaq
Jul 14Nymox to file for Fexapotide approval by mid-September
May 06Nymox under pressure on $8M private placement
Apr 28What You Need To Know About Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) Investor Composition
Mar 01Shareholder Returns
| NYMX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -17.4% | -4.7% | -3.7% |
| 1Y | -25.7% | -2.7% | 20.2% |
Return vs Industry: NYMX.F underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: NYMX.F underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| NYMX.F volatility | |
|---|---|
| NYMX.F Average Weekly Movement | 26.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NYMX.F's share price has been volatile over the past 3 months.
Volatility Over Time: NYMX.F's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Paul Averback | nymox.com |
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure.
Nymox Pharmaceutical Corporation Fundamentals Summary
| NYMX.F fundamental statistics | |
|---|---|
| Market cap | US$28.01m |
| Earnings (TTM) | -US$4.87m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.7x
P/E RatioIs NYMX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYMX.F income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.87m |
| Earnings | -US$4.87m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.052 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NYMX.F perform over the long term?
See historical performance and comparison